In general, all OVA-targeted heterologous prime-boost regimens led to improved survival of tumor-bearing mice, with rAd5-OVA/MG1-OVA and aDEC205-OVA/MG1-OVA regimens being the most effective (30% complete remission). This evidence concerns the gene MUC5B and neoplasm.